Hematopoietic stem cell transplantation in Zagreb: the first 40 years

Hematopoietic stem cell transplantation is the most effective treatment for acute leukemia, severe aplastic anemia, and some hereditary hematological disorders. The principal source of stem cells in this procedure are bone marrow and peripheral blood cells. In recent years, the transplantation outcome has significantly improved. The availability of the donor no longer poses a problem, as transplantation has been performed routinely from related, unrelated, and haploidentical donors. A high success rate has been reported in elderly patients transplanted with reduced-intensity conditioning. Improved patient care has decreased toxicity and mortality after treatment. This article gives an overview of the 40-year history of the Zagreb transplant program. It also discusses the use of hematopoietic stem cell transplantation in various hematological disorders, with a special emphasis on the publications by the Zagreb transplant team.

• Publication year

  2023

• Venue

  Croatian Medical Journal

• Publication date

  2023-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3325/cmj.2023.64.123PMID 37131314PMCID 10183962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chronic gvhd dictionary—eurograft cost action initiative consensus report

  2022cited by this paper
• Various approaches for accessing the influence of human leukocyte antigens disparity in haploidentical stem cell transplantation

  2022cited by this paper
• Comparisons Between modified PTCY and G-CSF/ATG Regimens for Haploidentical Transplantation in Patients with Aplastic Anemia.

  2022cited by this paper
• Blinatumomab is associated with favorable outcomes in patients with B‐cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10−4 and higher

  2022cited by this paper
• Autologous stem cell transplantation (ASCT) for acute myeloid leukemia in patients in first complete remission after one versus two induction courses: A study from the ALWP of the EBMT

  2022cited by this paper
• Allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis

  2022cited by this paper
• Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years

  2021cited by this paper
• CAR T-cells in acute lymphoblastic leukemia: Current results.

  2021cited by this paper
• Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia

  2021cited by this paper
• Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

  2021cited by this paper
• Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease

  2020cited by this paper
• Tisagenlecleucel in Acute Lymphoblastic Leukemia: A Review of the Literature and Practical Considerations

  2020cited by this paper
• Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study

  2020cited by this paper
• Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.

  2018cited by this paper
• Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

  2018cited by this paper
• Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for

  2018cited by this paper
• Autologous blood as a source of platelet gel for the effective and safe treatment of oral chronic graft‐versus‐host disease

  2018cited by this paper
• Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study.

  2018cited by this paper
• How I treat acquired aplastic anemia.

  2017cited by this paper
• Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

  2017cited by this paper
• A Review of Autologous Stem Cell Transplantation in Lymphoma

  2017cited by this paper
• Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

  2017cited by this paper
• Chronic graft-vs-host disease in 2016: a major challenge and an opportunity

  2016cited by this paper
• Glycoprotein YKL-40: a novel biomarker of chronic graft-vs-host disease activity and severity?

  2016cited by this paper
• High frequency of cutaneous manifestations including vitiligo and alopecia areata in a prospective cohort of patients with chronic graft-vs-host disease

  2016cited by this paper
• Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.

  2016cited by this paper
• Hematopoietic stem cell transplantation for patients with AML in first complete remission.

  2016cited by this paper
• The effect of HLA allele and haplotype polymorphisms on donor matching in hematopoietic stem cell transplantation - Croatian experience.

  2016cited by this paper
• Precision medicine--personalized, problematic, and promising.

  2015cited by this paper
• The role of hematopoietic stem cell transplantation in chronic myeloid leukemia

  2015cited by this paper
• Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.

  2015cited by this paper
• Autologous stem cell transplantation for adult acute leukemia in 2015: time to rethink? Present status and future prospects

  2015cited by this paper
• Reduced-intensity conditioned allogeneic SCT in adults with AML

  2015cited by this paper
• Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.

  2015cited by this paper
• Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT

  2015cited by this paper
• Current outcome of HLA identical sibling versus unrelated donor transplants in severe aplastic anemia: an EBMT analysis

  2015cited by this paper
• Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia.

  2015cited by this paper
• Similar outcome of upfront‐unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT

  2015cited by this paper
• Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.

  2014cited by this paper
• Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis.

  2013cited by this paper
• Role of autologous bone marrow transplant in multiple myeloma

  2012cited by this paper
• Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.

  2012cited by this paper
• Bone marrow versus peripheral blood as the stem cell source for sibling transplants in acquired aplastic anemia: survival advantage for bone marrow in all age groups

  2012cited by this paper
• How I treat acquired aplastic anemia.

  2012cited by this paper
• Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity

  2011cited by this paper
• Three decades of transplantation for chronic myeloid leukemia: what have we learned?

  2011cited by this paper
• Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care?

  2010cited by this paper
• Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials.

  2009cited by this paper
• [Twenty years of severe aplastic anemia treatment at Department of Hematology, University Department of Medicine, Zagreb University Hospital Center, Zagreb, Croatia].

  2009cited by this paper
• Status of minimal residual disease after induction predicts outcome in both standard and high‐risk Ph‐negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4‐2002 MRD Study

  2008cited by this paper
• HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.

  2008cited by this paper
• Et al

  2008cited by this paper
• Post-remission treatment for adult patients with acute lymphoblastic leukemia in first remission: is there a role for autologous stem cell transplantation?

  2007cited by this paper
• Acute myeloid leukemia and the position of autologous stem cell transplantation.

  2007cited by this paper
• Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia.

  2007cited by this paper
• Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT).

  2007cited by this paper
• [Umbilical cord blood as a source of stem cells].

  2006cited by this paper
• In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin

  2006cited by this paper
• Repetitive DNA polymorphisms in following chimerism after allogeneic bone marrow transplantation

  2005cited by this paper
• National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report.

  2005cited by this paper
• 2014 National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: preface to the series.

  2005cited by this paper
• Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients <or=50 years old in first complete remission: results of the EORTC ALL-3 trial.

  2004cited by this paper
• Evolution of hematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey.

  2004cited by this paper
• THE EVALUATION OF MIXED CHIMERISM IN BONE MARROW TRANSPLANTATION PROGRAM IN CROATIA

  2004cited by this paper
• Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin’s lymphoma for patients ≤£ 50 years old in first complete remission: results of the EORTC ALL-3 trial

  2004cited by this paper
• Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.

  2003cited by this paper
• Autologous stem cell transplantation for adult acute leukemia

  2002cited by this paper
• Treatment of murine leukaemia with x-rays and homologous bone marrow: II. 1957.

  2001cited by this paper
• Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience.

  2000cited by this paper
• A history of haemopoietic cell transplantation

  1999cited by this paper
• Treatment of chronic myeloid leukemia in relapse after umbilical cord blood transplantation.

  1998cited by this paper
• Bone marrow transplantation for severe aplastic anemia: has outcome improved?

  1997cited by this paper
• Allogeneic bone marrow transplantation for acute leukaemia--IGCI experience. International Group for Chemo-Immunotherapy.

  1996cited by this paper
• Allogeneic bone marrow transplantation for acute leukemia-IGCI experience

  1996cited by this paper
• Anxiety as a possible predictor of acute GVHD.

  1996cited by this paper
• Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group.

  1995cited by this paper
• Autologous bone marrow transplantation for haematological malignancies--experiences of the centre of Zagreb.

  1995cited by this paper
• An autopsy study of systemic fungal infections in patients with hematologic malignancies

  1995cited by this paper
• Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.

  1995cited by this paper
• Secondary solid malignant tumors occurring after bone marrow transplantation for severe aplastic anemia given thoraco-abdominal irradiation.

  1994cited by this paper
• Prostaglandin E2 for prophylaxis of oral mucositis following BMT.

  1993cited by this paper
• Umbilical cord blood transplantation in a patient with Philadelphia chromosome-positive chronic myeloid leukemia.

  1993cited by this paper
• Total body irradiation with or without lung shielding for allogeneic bone marrow transplantation.

  1992cited by this paper
• [Bone marrow transplantation in the treatment of severe aplastic anemia].

  1991cited by this paper
• Combination of cyclosporin and methotrexate for prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation for leukemia.

  1989cited by this paper
• [Treatment of neoplastic hematologic diseases with intensive radio-chemotherapy and transplantation of cryopreserved autologous bone marrow].

  1989cited by this paper
• Bone marrow transplantation for severe aplastic anemia from donors other than HLA identical siblings: a report of the BMT Working Party.

  1988cited by this paper
• Transplanted technology: Third World options and First World science.

  1987cited by this paper
• Experience with bone marrow transplantation for severe aplastic anemia and leukemia. Two years experience with 31 patients in Zagreb (Yugoslavia).

  1986cited by this paper
• [Transplantation of bone marrow in the treatment of severe aplastic anemia].

  1984cited by this paper
• [Report of the expert counsel regarding the location and organization of the center for bone marrow transplantation].

  1979cited by this paper
• [Conference on the needs and possibilities of clinical bone marrow transplantation. introduction (author's transl)].

  1978cited by this paper
• Immunology and genetics of transplantation.

  1977cited by this paper
• ACUTE GRAFT‐VERSUS-HOST REACTION IN MICE

  1976cited by this paper
• Acute graft-versus-host reaction in mice. 3. Organ distribution of injected 51 chromium labeled lymphocytes.

  1976cited by this paper
• Acute graft-versus-host reaction in mice. I. Cellular events.

  1976cited by this paper
• Rescue from graft-versus-host disease.

  1975cited by this paper
• Time pattern of antileukemic effect of graft-versus-host reaction in mice.

  1971cited by this paper
• Time pattern of the antileukemic effect of graft-versus-host reaction in mice.

  1971cited by this paper
• Transient graft-versus-host reaction in the treatment of leukemia in mice.

  1969cited by this paper

• Advancing Hematopoietic Stem Cell Transplantation Typing: Harnessing Hyperledger Fabric’s Blockchain Architecture

  2024cites this paper
• Forty years of hematopoietic stem cell transplantation in Croatia: First-World options and First-World science

  2023cites this paper